NEW YORK (GenomeWeb News) – Compugen said today that it will screen peptide candidates for three Pfizer drug targets.

Under the collaboration, Compugen will use its predictive models, algorithms, and computational biology methods to discover and synthesize molecules for the drug maker. Pfizer will pay Compugen for the research, and it will have the right to options for worldwide and exclusive milestones and licenses to develop and commercialize the selected candidates, Compugen said.

Compugen said it expects the studies to take a few months.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The Kansas City Star examines issues surrounding newborn genome sequencing.

Researchers say their Research Resource Identifier citation format is catching on, Nature News reports.

In Science this week: the Human Silencing Hub protein complex, and more.

Heads of various research funding agencies discuss how to encourage scientific breakthroughs, ScienceInsider reports.